Mednax appoints James D. Swift as COO; shareholders reject say-on-pay

Pediatrix Medical Group, Inc.

James D. Swift, MD promoted from EVP/Chief Development Officer to EVP/COO, effective May 12, 2022.
Say-on-pay vote failed: 45.2 million against vs 34.6 million for (56.6% against).
All director nominees elected; Weiss and Starcher each received over 9 million against votes.
Ratification of PwC as auditor for FY2022 passed with 78.3 million votes for.
Shareholders approved Second Amended and Restated Articles of Incorporation.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

James D. Swift

Chief Operating Officer

MD · Pediatrix Medical Group, Inc.

Effective: 2022-05-12
Filed: May 17, 2022, 7:59 PM ET

On May 12, 2022, Mednax, Inc., a Florida corporation (the “Company”), appointed James D. Swift, M.D. as an Executive Vice President and the Company’s Chief Operating Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

James D. Swift was appointed as Chief Operating Officer at Pediatrix Medical Group, Inc..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On May 12, 2022, Mednax, Inc., a Florida corporation (the “Company”), appointed James D. Swift, M.D. as an Executive Vice President and the Company’s Chief Operating Officer.

View on SEC.gov

Pediatrix Medical Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-010201

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.